Have a feature idea you'd love to see implemented?
Let us know!
CUE Cue Biopharma Inc
Price (delayed)
$1.03
Market cap
$65.25M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.91
Enterprise value
$39.5M
Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body to transform the
Highlights
CUE's revenue has surged by 150% year-on-year and by 15% since the previous quarter
The gross profit has soared by 150% year-on-year and by 15% since the previous quarter
The company's equity fell by 41% YoY but it rose by 17% QoQ
Cue Biopharma's quick ratio has decreased by 34% YoY but it has increased by 9% QoQ
Key stats
What are the main financial stats of CUE
Market
Valuations
Earnings
Shares outstanding
63.35M
Market cap
$65.25M
Enterprise value
$39.5M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.98
Price to sales (P/S)
5.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.14
Revenue
$9.53M
EBIT
-$43.46M
EBITDA
-$40.02M
Free cash flow
-$38.23M
Per share
Balance sheet
Liquidity
EPS
-$0.91
Free cash flow per share
-$0.75
Book value per share
$0.52
Revenue per share
$0.19
TBVPS
$0.87
Total assets
$44.81M
Total liabilities
$19.44M
Debt
$9.51M
Equity
$25.37M
Working capital
$20.47M
Debt to equity
0.37
Current ratio
2.22
Quick ratio
2.29
Net debt/EBITDA
0.64
Margins
Efficiency
Dividend
EBITDA margin
-419.9%
Gross margin
100%
Net margin
-468%
Operating margin
-479.4%
Return on assets
-88.1%
Return on equity
-156.4%
Return on invested capital
-900.3%
Return on capital employed
-155.1%
Return on sales
-455.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CUE stock price
How has the Cue Biopharma stock price performed over time
Intraday
-5.5%
1 week
-31.33%
1 month
-38.69%
1 year
-56.72%
YTD
-60.98%
QTD
36.03%
Financial performance
How have Cue Biopharma's revenue and profit performed over time
Revenue
$9.53M
Gross profit
$9.53M
Operating income
-$45.7M
Net income
-$44.61M
Gross margin
100%
Net margin
-468%
CUE's revenue has surged by 150% year-on-year and by 15% since the previous quarter
The gross profit has soared by 150% year-on-year and by 15% since the previous quarter
CUE's net margin has surged by 66% year-on-year and by 17% since the previous quarter
Cue Biopharma's operating margin has soared by 66% YoY and by 18% from the previous quarter
Growth
What is Cue Biopharma's growth rate over time
Valuation
What is Cue Biopharma stock price valuation
P/E
N/A
P/B
1.98
P/S
5.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.14
The EPS is up by 24% YoY and by 7% QoQ
The P/B is 52% below the 5-year quarterly average of 4.1 and 24% below the last 4 quarters average of 2.6
The company's equity fell by 41% YoY but it rose by 17% QoQ
CUE's revenue has surged by 150% year-on-year and by 15% since the previous quarter
The price to sales (P/S) is 93% lower than the 5-year quarterly average of 74.9 and 53% lower than the last 4 quarters average of 11.7
Efficiency
How efficient is Cue Biopharma business performance
The ROS has soared by 66% YoY and by 17% QoQ
Cue Biopharma's return on equity has shrunk by 58% YoY and by 9% QoQ
The ROA has contracted by 34% YoY and by 6% from the previous quarter
The ROIC has decreased by 34% QoQ
Dividends
What is CUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CUE.
Financial health
How did Cue Biopharma financials performed over time
The total assets is 130% greater than the total liabilities
The total assets has declined by 35% year-on-year but it is up by 6% since the previous quarter
Cue Biopharma's quick ratio has decreased by 34% YoY but it has increased by 9% QoQ
CUE's debt is 63% smaller than its equity
CUE's debt is down by 42% year-on-year and by 16% since the previous quarter
The company's equity fell by 41% YoY but it rose by 17% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.